- Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
On 6ix: 6ix.com/news/vera-therapeutics-announces-atacicept-achieved-46-proteinuria-reduction-origin-phase
Watch Vera Therapeutics' latest callVera Therapeutics (NASDAQ:VERA) Q3 2026 Earnings Call · Replay · Nov 5Read the transcript of Vera Therapeutics (NASDAQ:VERA) Q3 2026 Earnings CallVera Therapeutics, Inc. on 6ix
In the deck
Story so far
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
- Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
- Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
Earlier from Vera Therapeutics
- Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
- Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
- Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
- Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor
Later from Vera Therapeutics
- Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
- Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
- Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
Follow Vera Therapeutics into a list and get an email when it puts out news.
Follow Vera Therapeutics